Seven weeks into his job as FDA commissioner, Marty Makary, MD, MPH, held his own answering a barrage of sometimes ...

4D-ACS trial investigators found that after placement of a drug-coated stent (DCS), the incidence of net adverse clinical ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

CHICAGO -- Artificial intelligence (AI) assistance appeared to enhance pathologists' accuracy in identifying HER2-low or ...